Donor-Derived Lymphomas Mostly Develop in Allograft

Significantly shorter time to diagnosis for post-transplant lymphomas of donor origin

FRIDAY, June 17 (HealthDay News) -- The majority of post-transplant lymphoproliferative disorders (PTLDs) that are localized in the allograft are of donor origin and are diagnosed earlier, according to a study published in the June issue of the American Journal of Transplantation.

Jerome Olagne, from the Strasbourg University Hospital in France, and colleagues investigated the features and outcome of PTLD according to the origin of the lymphoma (donor or recipient). A total of 43 specimens from kidney recipients were analyzed by histochemistry, using fluorescent hybridization of the Y chromosome, and with microsatellite analysis of multiple short tandem repeat loci.

The investigators found that 16 tumors were of donor origin, and 27 recipient origin. The time to diagnosis was significantly shorter in patients with PTLD of donor origin. Ten-year survival was similar regardless of the lymphoma origin, but analysis of PTLD-related mortality showed a trend to better survival in patients with donor-origin lymphomas. Of the 21 PTLDs localized in the allograft, 14 were donor-derived and seven were recipient-derived, with no differences seen between the groups.

"Using a large series, we showed that the great majority of donor PTLDs developed in the allograft, with a shorter time to diagnosis than for recipient lymphomas," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing